{"id":68994,"date":"2026-03-12T15:22:39","date_gmt":"2026-03-12T15:22:39","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68994"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"cjc-1295-with-dac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/cjc-1295-with-dac\/","title":{"rendered":"CJC-1295 with DAC"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is CJC-1295 with DAC?<\/h3>\n

CJC-1295 with DAC<\/strong> is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) modified with a Drug Affinity Complex (DAC)<\/strong> that binds plasma albumin covalently. The albumin binding extends plasma half-life from ~30 minutes to approximately 7\u00a0days, enabling weekly or twice-weekly research dosing. It is supplied in 2\u00a0mg and 5\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Mit kapsz a MedsBase-n\u00e1l:<\/strong> Kutat\u00e1si min\u0151s\u00e9g\u0171 liofiliz\u00e1lt peptidok \u00b7 HPLC \u226599% tisztas\u00e1g (tan\u00fas\u00edtv\u00e1ny k\u00e9r\u00e9sre) \u00b7 Diszkr\u00e9t, h\u0151m\u00e9rs\u00e9klet-stabil csomagol\u00e1s \u00b7 Vil\u00e1gszerte peptid fut\u00e1rszolg\u00e1lat \u00b7 1,400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a><\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifik\u00e1ci\u00f3<\/th>\nR\u00e9szlet<\/th>\n<\/tr>\n<\/thead>\n
CAS sz\u00e1m<\/strong><\/td>\n863288-34-0<\/td>\n<\/tr>\n
Molekul\u00e1ris k\u00e9plet<\/strong><\/td>\nC165<\/sub>H269<\/sub>N47<\/sub>O46<\/sub><\/td>\n<\/tr>\n
Molekulat\u00f6meg<\/strong><\/td>\n3647.25 Da<\/td>\n<\/tr>\n
Szekvencia<\/strong><\/td>\nD-Ala-Tyr-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2<\/sub> conjugated to maleimidopropionyl-Lys (DAC linker for albumin binding)<\/td>\n<\/tr>\n
Forma<\/strong><\/td>\nLiofiliz\u00e1lt por (vagy a sz\u00e1ll\u00edtott form\u00e1ban)<\/td>\n<\/tr>\n
Tisztas\u00e1g<\/strong><\/td>\n\u226599% (HPLC-vel ellen\u0151rizve, COA ig\u00e9ny szerint)<\/td>\n<\/tr>\n
T\u00e1rol\u00e1s<\/strong><\/td>\nLiofiliz\u00e1lt: 2\u20138 \u00b0C (h\u0171t\u0151szekr\u00e9ny) munkak\u00e9szletk\u00e9nt; \u221220 \u00b0C hossz\u00fa t\u00e1v\u00fa t\u00e1rol\u00e1sra lez\u00e1ratlan \u00fcvegek eset\u00e9n. Rekonstitu\u00e1lt: 2\u20138 \u00b0C, haszn\u00e1lat ~30 napon bel\u00fcl. V\u00e9dj\u00fck a f\u00e9nyt\u0151l. Ne fagyassza-v\u00e1lassza fel az \u00fajra\u00e1ll\u00edtott oldatot.<\/td>\n<\/tr>\n
Oldhat\u00f3s\u00e1g<\/strong><\/td>\nBakt\u00e9riumstatikus v\u00edz (aj\u00e1nlott) vagy steril v\u00edz r\u00f6videbb haszn\u00e1latra<\/td>\n<\/tr>\n
Kutat\u00e1si c\u00e9lra<\/strong><\/td>\nCsak laborat\u00f3riumi kutat\u00e1si c\u00e9lra. Nem haszn\u00e1lhat\u00f3 hum\u00e1n vagy \u00e1llatgy\u00f3gy\u00e1szati diagnosztikai vagy ter\u00e1pi\u00e1s c\u00e9lra.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is CJC-1295 with DAC?<\/h2>\n

CJC-1295<\/strong> is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone (GHRH), specifically a modified form of the biologically-active GHRH (1-29) fragment. The “with DAC<\/strong>” suffix refers to a proprietary Drug Affinity Complex (DAC)<\/strong> \u2014 a maleimidopropionic acid residue attached to lysine-30 \u2014 which forms a covalent bond with serum albumin cysteine-34 in vivo<\/em>.<\/p>\n

That albumin tether is the key innovation. Native GHRH has a plasma half-life measured in minutes (rapid DPP-IV degradation); CJC-1295 with DAC circulates bound to albumin for approximately 7 nap<\/strong>, enabling weekly or twice-weekly research dosing while sustaining GH\/IGF-1 elevation between injections. This is a fundamentally different pharmacokinetic profile from the “without DAC” version (sometimes called Mod GRF 1-29) which retains native GHRH’s short half-life. Developed by ConjuChem, CJC-1295 is laborat\u00f3riumi kutat\u00e1si c\u00e9lra szolg\u00e1l<\/strong> and is not intended for human or veterinary diagnosis or therapy. For mechanism, research context, and stacking protocols, see our Ipamorelin & CJC-1295 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Extended-Release GHRH Agonism<\/h2>\n

CJC-1295 with DAC acts through two sequential mechanisms:<\/p>\n